BREAKING NEWS FROM LIFNANO-Rx

Our Spin-Out Company, SWITCH-RX, is finalist for OBN's International Award "Best Start-Up Biotechnology Company 2021" . The Winner is to be announced at the Finalists' dinner 25th November 2021 in Oxford University's famous Ashmolean Museum.

ENGINEERED TO KILL CANCER: SWITCH's lead product is SIX-IO™  - designed to target cancer-specific immune cells within solid cancers and switch them directly into "cancer killer" cells. 

Founded in 2020, SWITCH-RX is a synthetic bio-mimetic, SIX-IO is (i) off-the-shelf; (ii) universal for all types of cancer; (iii) relatively low cost and sustainable; (iv) high efficacy and safety; (v) scalable. 

ADDING FURTHER VALUE FOR INVESTORS

SWITCH-RX brings a highly disruptive, innovative approach to the Global Oncology Market. Unlike cell-based therapies, SIX-IO is uniquely differentiating - providing a simpler, safer, cleaner, scalable, universal, off-the-shelf therapy. 

SWITCH-RX is a Spin-Out of LIFNanoRx

CONTACT      s.metcalfe@LIFNano.com